Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 2022 Earnings Presentation
8 slides from Angiodynamics's earnings presentation, Sep 30, 2021
Slide 1: First Quarter 2022 Earnings Presentation
ANGIODYNAMICS First Quarter 2022 Earnings PresentationSeptember 30, 2021 *
Slide 2: Forward-Looking Statement
* Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q1 Highlights
Corporate Developments – Q1 Highlights * Continued focused investment in our 3 key Med Tech platforms: Auryon, Mechanical Thrombectomy & NanoKnife NanoKnife DIRECT study: 26 active sites, consistent with last quarter Encouraged by overall execution of the study in the current environment Revised FY2
Slide 4: Highlights – Financial Performance
First Quarter Highlights Q1 FY2022 Q1 FY2021 YOY Change Revenue $76,971 $70,216 9.6% Gross Margin 52.1% 50.9% 120 bps Net Loss ($6,972) ($4,268) ($2,704) GAAP EPS ($0.18) ($0.11) ($0.07) Adjusted EPS ($0.02) $0.02 ($0.04) Adjusted EBITDA $3,570 $4,466 ($896) Financial Performance$ in thousands (exce
Slide 5: Highlights – Sales Growth Over Prior Periods
First Quarter Highlights – Sales Growth Over Prior Periods Endovascular Therapies Q1 FY2022 Auryon NA* AngioVac® 12% Thrombolytic (8%) Core Peripheral 14% Venous Insufficiency 10% Vascular Access Q1 FY2022 Midlines** (38%) C3 62% PICCs** (23%) Ports 21% Dialysis (8%) Oncology Q1 FY2022 NanoKnife® Ca
Slide 6: FY2022 Results (unaudited)
First Quarter FY2022 Results (unaudited) $ in thousands (except per share data) Q1 FY2022 Q1 FY2021 Change Revenue $76,971 $70,216 9.6% Med Tech Med Device $17,619$59,352 $10,486$59,730 68.0%(0.6%) Endovascular Therapies Vascular Access Oncology $38,058$24,957$13,956 $29,857$28,105$12,254 27.5%(11.2
Slide 7: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation *
Slide 8: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to re